Cardiovascular diseases (CVDs) are the main cause of death among patients with type 2
diabetes mellitus (T2DM), particularly in low-and middle-income countries. To effectively …

SGLT2 inhibitors and GLP-1 receptor agonists are used in patients with type 2 diabetes as
glucose lowering therapies, with additional benefits of weight loss and blood pressure …

Background Sodium–glucose cotransporter 2 inhibitors reduce the risk of hospitalization for
heart failure in patients with heart failure and a reduced ejection fraction, but their effects in …

The American Diabetes Association and the European Association for the Study of Diabetes
have briefly updated their 2018 recommendations on management of hyperglycemia, based …

In accordance with the comorbidity-inflammation paradigm, comorbidities and especially
metabolic comorbidities are presumed to drive development and severity of heart failure with …

Diabetes mellitus predisposes affected individuals to a significant spectrum of
cardiovascular complications, one of the most debilitating in terms of prognosis is heart …

Background: SGLT2 (sodium-glucose cotransporter 2) inhibitors lower cardiovascular
events in type 2 diabetes mellitus but whether they promote direct cardiac effects remains …

Background The principal biological processes that characterize heart failure with a
preserved ejection fraction (HFpEF) are systemic inflammation, epicardial adipose tissue …

Acute decompensated heart failure (ADHF) is one of the leading admission diagnoses
worldwide, yet it is an entity with incompletely understood pathophysiology and limited …

Heart failure (HF) is a growing public health issue. As many as 1 in 5 people are expected to
develop HF during their lifetime, 1 with an estimated 63 million people affected worldwide. 2 …